nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—ADRA1B—vas deferens—testicular cancer	0.112	0.355	CbGeAlD
Loxapine—HTR7—vas deferens—testicular cancer	0.065	0.207	CbGeAlD
Loxapine—HTR7—vein—testicular cancer	0.0276	0.0878	CbGeAlD
Loxapine—HTR2A—vein—testicular cancer	0.0172	0.0548	CbGeAlD
Loxapine—DRD4—testis—testicular cancer	0.00814	0.0259	CbGeAlD
Loxapine—HTR1E—female gonad—testicular cancer	0.00791	0.0251	CbGeAlD
Loxapine—CHRM4—testis—testicular cancer	0.00615	0.0196	CbGeAlD
Loxapine—DRD5—female gonad—testicular cancer	0.00604	0.0192	CbGeAlD
Loxapine—ADRA2C—seminal vesicle—testicular cancer	0.00452	0.0144	CbGeAlD
Loxapine—SLC6A2—gonad—testicular cancer	0.00368	0.0117	CbGeAlD
Loxapine—HRH2—lymph node—testicular cancer	0.00365	0.0116	CbGeAlD
Loxapine—ADRA2A—seminal vesicle—testicular cancer	0.0036	0.0115	CbGeAlD
Loxapine—HTR7—gonad—testicular cancer	0.00355	0.0113	CbGeAlD
Loxapine—SLC6A3—testis—testicular cancer	0.00329	0.0105	CbGeAlD
Loxapine—HTR2A—embryo—testicular cancer	0.00326	0.0104	CbGeAlD
Loxapine—CHRM3—female gonad—testicular cancer	0.00303	0.00964	CbGeAlD
Loxapine—CHRM3—testis—testicular cancer	0.00269	0.00855	CbGeAlD
Loxapine—SLC6A2—testis—testicular cancer	0.00266	0.00844	CbGeAlD
Loxapine—ADRA2C—female gonad—testicular cancer	0.00265	0.00843	CbGeAlD
Loxapine—ADRA2A—gonad—testicular cancer	0.0026	0.00828	CbGeAlD
Loxapine—HTR7—testis—testicular cancer	0.00256	0.00813	CbGeAlD
Loxapine—DRD2—testis—testicular cancer	0.00242	0.00769	CbGeAlD
Loxapine—ADRA2C—testis—testicular cancer	0.00235	0.00748	CbGeAlD
Loxapine—HTR2A—gonad—testicular cancer	0.00221	0.00704	CbGeAlD
Loxapine—HRH1—female gonad—testicular cancer	0.00215	0.00685	CbGeAlD
Loxapine—ADRA2A—female gonad—testicular cancer	0.00212	0.00673	CbGeAlD
Loxapine—SLC6A2—lymph node—testicular cancer	0.00192	0.00612	CbGeAlD
Loxapine—HRH1—testis—testicular cancer	0.00191	0.00607	CbGeAlD
Loxapine—ADRA2A—testis—testicular cancer	0.00188	0.00597	CbGeAlD
Loxapine—ADRA2C—lymph node—testicular cancer	0.0017	0.00542	CbGeAlD
Loxapine—Photosensitivity—Methotrexate—testicular cancer	0.0016	0.00298	CcSEcCtD
Loxapine—HTR2A—testis—testicular cancer	0.0016	0.00507	CbGeAlD
Loxapine—Mediastinal disorder—Cisplatin—testicular cancer	0.00159	0.00297	CcSEcCtD
Loxapine—Hypotension—Bleomycin—testicular cancer	0.00159	0.00297	CcSEcCtD
Loxapine—Oedema—Dactinomycin—testicular cancer	0.00159	0.00296	CcSEcCtD
Loxapine—Asthenia—Chlorambucil—testicular cancer	0.00158	0.00295	CcSEcCtD
Loxapine—Alopecia—Cisplatin—testicular cancer	0.00156	0.00291	CcSEcCtD
Loxapine—Pruritus—Chlorambucil—testicular cancer	0.00156	0.00291	CcSEcCtD
Loxapine—Cough—Ifosfamide—testicular cancer	0.00156	0.0029	CcSEcCtD
Loxapine—Thrombocytopenia—Dactinomycin—testicular cancer	0.00156	0.0029	CcSEcCtD
Loxapine—Convulsion—Ifosfamide—testicular cancer	0.00155	0.00288	CcSEcCtD
Loxapine—Dry eye—Doxorubicin—testicular cancer	0.00154	0.00288	CcSEcCtD
Loxapine—Hypertension—Ifosfamide—testicular cancer	0.00154	0.00287	CcSEcCtD
Loxapine—Paraesthesia—Bleomycin—testicular cancer	0.00153	0.00285	CcSEcCtD
Loxapine—Dyspnoea—Bleomycin—testicular cancer	0.00152	0.00283	CcSEcCtD
Loxapine—Chest pain—Ifosfamide—testicular cancer	0.00152	0.00283	CcSEcCtD
Loxapine—Photosensitivity—Epirubicin—testicular cancer	0.00149	0.00279	CcSEcCtD
Loxapine—Hypersensitivity—Vinblastine—testicular cancer	0.00149	0.00277	CcSEcCtD
Loxapine—Muscle spasms—Cisplatin—testicular cancer	0.00148	0.00276	CcSEcCtD
Loxapine—Angiopathy—Etoposide—testicular cancer	0.00147	0.00274	CcSEcCtD
Loxapine—Confusional state—Ifosfamide—testicular cancer	0.00147	0.00274	CcSEcCtD
Loxapine—Mediastinal disorder—Etoposide—testicular cancer	0.00146	0.00272	CcSEcCtD
Loxapine—Oedema—Ifosfamide—testicular cancer	0.00146	0.00272	CcSEcCtD
Loxapine—Vision blurred—Cisplatin—testicular cancer	0.00145	0.0027	CcSEcCtD
Loxapine—Asthenia—Vinblastine—testicular cancer	0.00145	0.0027	CcSEcCtD
Loxapine—Tremor—Cisplatin—testicular cancer	0.00144	0.00269	CcSEcCtD
Loxapine—Alopecia—Etoposide—testicular cancer	0.00143	0.00267	CcSEcCtD
Loxapine—Cerebrovascular accident—Methotrexate—testicular cancer	0.00143	0.00267	CcSEcCtD
Loxapine—Nervous system disorder—Ifosfamide—testicular cancer	0.00143	0.00266	CcSEcCtD
Loxapine—Thrombocytopenia—Ifosfamide—testicular cancer	0.00143	0.00266	CcSEcCtD
Loxapine—Feeling abnormal—Bleomycin—testicular cancer	0.0014	0.00262	CcSEcCtD
Loxapine—Vomiting—Chlorambucil—testicular cancer	0.0014	0.00261	CcSEcCtD
Loxapine—HRH1—lymph node—testicular cancer	0.00138	0.0044	CbGeAlD
Loxapine—Photosensitivity—Doxorubicin—testicular cancer	0.00138	0.00258	CcSEcCtD
Loxapine—Dysgeusia—Etoposide—testicular cancer	0.00138	0.00257	CcSEcCtD
Loxapine—Leukopenia—Cisplatin—testicular cancer	0.00138	0.00257	CcSEcCtD
Loxapine—Fatigue—Dactinomycin—testicular cancer	0.00137	0.00256	CcSEcCtD
Loxapine—Hypotension—Ifosfamide—testicular cancer	0.00136	0.00254	CcSEcCtD
Loxapine—ADRA2A—lymph node—testicular cancer	0.00136	0.00432	CbGeAlD
Loxapine—Muscle spasms—Etoposide—testicular cancer	0.00136	0.00253	CcSEcCtD
Loxapine—Cerebrovascular accident—Epirubicin—testicular cancer	0.00134	0.0025	CcSEcCtD
Loxapine—Dizziness—Vinblastine—testicular cancer	0.00133	0.00249	CcSEcCtD
Loxapine—Convulsion—Cisplatin—testicular cancer	0.00133	0.00249	CcSEcCtD
Loxapine—Feeling abnormal—Dactinomycin—testicular cancer	0.00131	0.00244	CcSEcCtD
Loxapine—Nausea—Chlorambucil—testicular cancer	0.00131	0.00244	CcSEcCtD
Loxapine—Paraesthesia—Ifosfamide—testicular cancer	0.00131	0.00244	CcSEcCtD
Loxapine—Dyspnoea—Ifosfamide—testicular cancer	0.0013	0.00242	CcSEcCtD
Loxapine—Somnolence—Ifosfamide—testicular cancer	0.0013	0.00241	CcSEcCtD
Loxapine—Vomiting—Vinblastine—testicular cancer	0.00128	0.00239	CcSEcCtD
Loxapine—Headache—Vinblastine—testicular cancer	0.00126	0.00236	CcSEcCtD
Loxapine—Leukopenia—Etoposide—testicular cancer	0.00126	0.00235	CcSEcCtD
Loxapine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00126	0.00235	CcSEcCtD
Loxapine—Fatigue—Ifosfamide—testicular cancer	0.00126	0.00234	CcSEcCtD
Loxapine—Oedema—Cisplatin—testicular cancer	0.00126	0.00234	CcSEcCtD
Loxapine—Hypersensitivity—Bleomycin—testicular cancer	0.00126	0.00234	CcSEcCtD
Loxapine—Constipation—Ifosfamide—testicular cancer	0.00125	0.00232	CcSEcCtD
Loxapine—Loss of consciousness—Etoposide—testicular cancer	0.00124	0.00231	CcSEcCtD
Loxapine—Cerebrovascular accident—Doxorubicin—testicular cancer	0.00124	0.00231	CcSEcCtD
Loxapine—Nervous system disorder—Cisplatin—testicular cancer	0.00123	0.0023	CcSEcCtD
Loxapine—Cough—Etoposide—testicular cancer	0.00123	0.00229	CcSEcCtD
Loxapine—Thrombocytopenia—Cisplatin—testicular cancer	0.00123	0.00229	CcSEcCtD
Loxapine—Tachycardia—Cisplatin—testicular cancer	0.00123	0.00229	CcSEcCtD
Loxapine—Asthenia—Bleomycin—testicular cancer	0.00122	0.00228	CcSEcCtD
Loxapine—Convulsion—Etoposide—testicular cancer	0.00122	0.00228	CcSEcCtD
Loxapine—Hypertension—Etoposide—testicular cancer	0.00122	0.00227	CcSEcCtD
Loxapine—Pruritus—Bleomycin—testicular cancer	0.00121	0.00225	CcSEcCtD
Loxapine—Feeling abnormal—Ifosfamide—testicular cancer	0.0012	0.00224	CcSEcCtD
Loxapine—Chest pain—Etoposide—testicular cancer	0.0012	0.00224	CcSEcCtD
Loxapine—Nausea—Vinblastine—testicular cancer	0.0012	0.00224	CcSEcCtD
Loxapine—Orthostatic hypotension—Epirubicin—testicular cancer	0.0012	0.00223	CcSEcCtD
Loxapine—Hypotension—Cisplatin—testicular cancer	0.00117	0.00219	CcSEcCtD
Loxapine—Hypersensitivity—Dactinomycin—testicular cancer	0.00117	0.00218	CcSEcCtD
Loxapine—Confusional state—Etoposide—testicular cancer	0.00116	0.00216	CcSEcCtD
Loxapine—Asthenia—Dactinomycin—testicular cancer	0.00114	0.00213	CcSEcCtD
Loxapine—Dysphagia—Epirubicin—testicular cancer	0.00113	0.00211	CcSEcCtD
Loxapine—Paraesthesia—Cisplatin—testicular cancer	0.00113	0.0021	CcSEcCtD
Loxapine—Thrombocytopenia—Etoposide—testicular cancer	0.00113	0.0021	CcSEcCtD
Loxapine—Tachycardia—Etoposide—testicular cancer	0.00112	0.00209	CcSEcCtD
Loxapine—Dyspnoea—Cisplatin—testicular cancer	0.00112	0.00209	CcSEcCtD
Loxapine—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00111	0.00207	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—testicular cancer	0.00111	0.00206	CcSEcCtD
Loxapine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00108	0.00202	CcSEcCtD
Loxapine—Vomiting—Bleomycin—testicular cancer	0.00108	0.00202	CcSEcCtD
Loxapine—Drowsiness—Methotrexate—testicular cancer	0.00108	0.00201	CcSEcCtD
Loxapine—Hypotension—Etoposide—testicular cancer	0.00108	0.002	CcSEcCtD
Loxapine—Rash—Bleomycin—testicular cancer	0.00107	0.002	CcSEcCtD
Loxapine—Dermatitis—Bleomycin—testicular cancer	0.00107	0.002	CcSEcCtD
Loxapine—Hypersensitivity—Ifosfamide—testicular cancer	0.00107	0.002	CcSEcCtD
Loxapine—Renal failure—Methotrexate—testicular cancer	0.00106	0.00198	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—testicular cancer	0.00105	0.00196	CcSEcCtD
Loxapine—Asthenia—Ifosfamide—testicular cancer	0.00105	0.00195	CcSEcCtD
Loxapine—Photosensitivity reaction—Epirubicin—testicular cancer	0.00104	0.00193	CcSEcCtD
Loxapine—Feeling abnormal—Cisplatin—testicular cancer	0.00103	0.00193	CcSEcCtD
Loxapine—Paraesthesia—Etoposide—testicular cancer	0.00103	0.00193	CcSEcCtD
Loxapine—Weight increased—Epirubicin—testicular cancer	0.00103	0.00192	CcSEcCtD
Loxapine—Pruritus—Ifosfamide—testicular cancer	0.00103	0.00192	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—testicular cancer	0.00103	0.00191	CcSEcCtD
Loxapine—Dyspnoea—Etoposide—testicular cancer	0.00103	0.00191	CcSEcCtD
Loxapine—Somnolence—Etoposide—testicular cancer	0.00102	0.00191	CcSEcCtD
Loxapine—Nausea—Bleomycin—testicular cancer	0.00101	0.00189	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—testicular cancer	0.00101	0.00189	CcSEcCtD
Loxapine—Vomiting—Dactinomycin—testicular cancer	0.00101	0.00188	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—testicular cancer	0.00101	0.00188	CcSEcCtD
Loxapine—Rash—Dactinomycin—testicular cancer	0.001	0.00187	CcSEcCtD
Loxapine—Renal failure—Epirubicin—testicular cancer	0.000994	0.00185	CcSEcCtD
Loxapine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000993	0.00185	CcSEcCtD
Loxapine—Fatigue—Etoposide—testicular cancer	0.000992	0.00185	CcSEcCtD
Loxapine—Jaundice—Epirubicin—testicular cancer	0.000986	0.00184	CcSEcCtD
Loxapine—Constipation—Etoposide—testicular cancer	0.000984	0.00183	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—testicular cancer	0.00097	0.00181	CcSEcCtD
Loxapine—Dizziness—Ifosfamide—testicular cancer	0.000963	0.0018	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000958	0.00179	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—testicular cancer	0.000955	0.00178	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—testicular cancer	0.000949	0.00177	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—testicular cancer	0.000948	0.00177	CcSEcCtD
Loxapine—Nausea—Dactinomycin—testicular cancer	0.000944	0.00176	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—testicular cancer	0.000944	0.00176	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—testicular cancer	0.000936	0.00174	CcSEcCtD
Loxapine—Vomiting—Ifosfamide—testicular cancer	0.000926	0.00173	CcSEcCtD
Loxapine—Hypersensitivity—Cisplatin—testicular cancer	0.000925	0.00173	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—testicular cancer	0.00092	0.00172	CcSEcCtD
Loxapine—Rash—Ifosfamide—testicular cancer	0.000919	0.00171	CcSEcCtD
Loxapine—Dermatitis—Ifosfamide—testicular cancer	0.000918	0.00171	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—testicular cancer	0.000912	0.0017	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—testicular cancer	0.000908	0.00169	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—testicular cancer	0.000903	0.00168	CcSEcCtD
Loxapine—Asthenia—Cisplatin—testicular cancer	0.000901	0.00168	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—testicular cancer	0.00088	0.00164	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—testicular cancer	0.000874	0.00163	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—testicular cancer	0.000873	0.00163	CcSEcCtD
Loxapine—Nausea—Ifosfamide—testicular cancer	0.000865	0.00161	CcSEcCtD
Loxapine—Alopecia—Methotrexate—testicular cancer	0.000857	0.0016	CcSEcCtD
Loxapine—Hypersensitivity—Etoposide—testicular cancer	0.000848	0.00158	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—testicular cancer	0.00084	0.00157	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000836	0.00156	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—testicular cancer	0.000827	0.00154	CcSEcCtD
Loxapine—Asthenia—Etoposide—testicular cancer	0.000826	0.00154	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—testicular cancer	0.000824	0.00154	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—testicular cancer	0.000818	0.00153	CcSEcCtD
Loxapine—Pruritus—Etoposide—testicular cancer	0.000814	0.00152	CcSEcCtD
Loxapine—Alopecia—Epirubicin—testicular cancer	0.000802	0.0015	CcSEcCtD
Loxapine—Vomiting—Cisplatin—testicular cancer	0.000799	0.00149	CcSEcCtD
Loxapine—HTR5A—Signaling Pathways—INSL3—testicular cancer	0.000796	0.00534	CbGpPWpGaD
Loxapine—Vision blurred—Methotrexate—testicular cancer	0.000796	0.00148	CcSEcCtD
Loxapine—Rash—Cisplatin—testicular cancer	0.000792	0.00148	CcSEcCtD
Loxapine—Dermatitis—Cisplatin—testicular cancer	0.000791	0.00148	CcSEcCtD
Loxapine—Tension—Epirubicin—testicular cancer	0.000775	0.00145	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—testicular cancer	0.000774	0.00144	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—testicular cancer	0.000762	0.00142	CcSEcCtD
Loxapine—Dizziness—Etoposide—testicular cancer	0.000761	0.00142	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—testicular cancer	0.00076	0.00142	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000757	0.00141	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—testicular cancer	0.000756	0.00141	CcSEcCtD
Loxapine—ADRB1—GPCR ligand binding—INSL3—testicular cancer	0.00075	0.00503	CbGpPWpGaD
Loxapine—Nausea—Cisplatin—testicular cancer	0.000746	0.00139	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—testicular cancer	0.000745	0.00139	CcSEcCtD
Loxapine—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	0.000743	0.00498	CbGpPWpGaD
Loxapine—Alopecia—Doxorubicin—testicular cancer	0.000742	0.00138	CcSEcCtD
Loxapine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00074	0.00497	CbGpPWpGaD
Loxapine—Cough—Methotrexate—testicular cancer	0.000737	0.00137	CcSEcCtD
Loxapine—SLC6A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000733	0.00491	CbGpPWpGaD
Loxapine—Convulsion—Methotrexate—testicular cancer	0.000732	0.00136	CcSEcCtD
Loxapine—Vomiting—Etoposide—testicular cancer	0.000732	0.00136	CcSEcCtD
Loxapine—HTR1E—Signaling by GPCR—INSL3—testicular cancer	0.000728	0.00488	CbGpPWpGaD
Loxapine—Agitation—Epirubicin—testicular cancer	0.000726	0.00135	CcSEcCtD
Loxapine—Rash—Etoposide—testicular cancer	0.000725	0.00135	CcSEcCtD
Loxapine—Dermatitis—Etoposide—testicular cancer	0.000725	0.00135	CcSEcCtD
Loxapine—Headache—Etoposide—testicular cancer	0.000721	0.00134	CcSEcCtD
Loxapine—Chest pain—Methotrexate—testicular cancer	0.000719	0.00134	CcSEcCtD
Loxapine—Tension—Doxorubicin—testicular cancer	0.000718	0.00134	CcSEcCtD
Loxapine—HTR1A—GPCR ligand binding—INSL3—testicular cancer	0.000717	0.00481	CbGpPWpGaD
Loxapine—Dysgeusia—Doxorubicin—testicular cancer	0.000716	0.00134	CcSEcCtD
Loxapine—HRH2—GPCR downstream signaling—INSL3—testicular cancer	0.000714	0.00479	CbGpPWpGaD
Loxapine—HTR2C—GPCR ligand binding—INSL3—testicular cancer	0.000714	0.00479	CbGpPWpGaD
Loxapine—DRD5—GPCR downstream signaling—INSL3—testicular cancer	0.000709	0.00476	CbGpPWpGaD
Loxapine—Syncope—Epirubicin—testicular cancer	0.000709	0.00132	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—testicular cancer	0.000707	0.00132	CcSEcCtD
Loxapine—Muscle spasms—Doxorubicin—testicular cancer	0.000703	0.00131	CcSEcCtD
Loxapine—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	0.0007	0.0047	CbGpPWpGaD
Loxapine—Confusional state—Methotrexate—testicular cancer	0.000695	0.0013	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—testicular cancer	0.000695	0.0013	CcSEcCtD
Loxapine—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	0.000694	0.00465	CbGpPWpGaD
Loxapine—Cough—Epirubicin—testicular cancer	0.00069	0.00129	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—testicular cancer	0.000689	0.00128	CcSEcCtD
Loxapine—Convulsion—Epirubicin—testicular cancer	0.000685	0.00128	CcSEcCtD
Loxapine—Nausea—Etoposide—testicular cancer	0.000683	0.00127	CcSEcCtD
Loxapine—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	0.000683	0.00458	CbGpPWpGaD
Loxapine—Hypertension—Epirubicin—testicular cancer	0.000682	0.00127	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—testicular cancer	0.000676	0.00126	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—testicular cancer	0.000675	0.00126	CcSEcCtD
Loxapine—Chest pain—Epirubicin—testicular cancer	0.000673	0.00125	CcSEcCtD
Loxapine—Agitation—Doxorubicin—testicular cancer	0.000672	0.00125	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—testicular cancer	0.000658	0.00123	CcSEcCtD
Loxapine—Syncope—Doxorubicin—testicular cancer	0.000656	0.00122	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—testicular cancer	0.000655	0.00122	CcSEcCtD
Loxapine—Confusional state—Epirubicin—testicular cancer	0.00065	0.00121	CcSEcCtD
Loxapine—HRH2—Signaling by GPCR—INSL3—testicular cancer	0.000648	0.00435	CbGpPWpGaD
Loxapine—Oedema—Epirubicin—testicular cancer	0.000645	0.0012	CcSEcCtD
Loxapine—DRD5—Signaling by GPCR—INSL3—testicular cancer	0.000644	0.00432	CbGpPWpGaD
Loxapine—Hypotension—Methotrexate—testicular cancer	0.000644	0.0012	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—testicular cancer	0.000643	0.0012	CcSEcCtD
Loxapine—Cough—Doxorubicin—testicular cancer	0.000638	0.00119	CcSEcCtD
Loxapine—Shock—Epirubicin—testicular cancer	0.000635	0.00118	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—testicular cancer	0.000634	0.00118	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—testicular cancer	0.000633	0.00118	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—testicular cancer	0.000631	0.00118	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—testicular cancer	0.000631	0.00118	CcSEcCtD
Loxapine—DRD2—GPCR ligand binding—INSL3—testicular cancer	0.00063	0.00422	CbGpPWpGaD
Loxapine—Tachycardia—Epirubicin—testicular cancer	0.000629	0.00117	CcSEcCtD
Loxapine—Insomnia—Methotrexate—testicular cancer	0.000623	0.00116	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—testicular cancer	0.000623	0.00116	CcSEcCtD
Loxapine—CHRM3—Integration of energy metabolism—STK11—testicular cancer	0.00062	0.00416	CbGpPWpGaD
Loxapine—HTR2A—GPCR ligand binding—INSL3—testicular cancer	0.00062	0.00416	CbGpPWpGaD
Loxapine—Paraesthesia—Methotrexate—testicular cancer	0.000619	0.00115	CcSEcCtD
Loxapine—HRH1—GPCR ligand binding—INSL3—testicular cancer	0.000618	0.00415	CbGpPWpGaD
Loxapine—CHRM1—GPCR ligand binding—INSL3—testicular cancer	0.000616	0.00413	CbGpPWpGaD
Loxapine—Dyspnoea—Methotrexate—testicular cancer	0.000614	0.00115	CcSEcCtD
Loxapine—CHRM3—GPCR ligand binding—INSL3—testicular cancer	0.000614	0.00412	CbGpPWpGaD
Loxapine—Somnolence—Methotrexate—testicular cancer	0.000613	0.00114	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—testicular cancer	0.000609	0.00114	CcSEcCtD
Loxapine—CHRM2—GPCR ligand binding—INSL3—testicular cancer	0.000608	0.00408	CbGpPWpGaD
Loxapine—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	0.000607	0.00407	CbGpPWpGaD
Loxapine—Hypotension—Epirubicin—testicular cancer	0.000603	0.00112	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—testicular cancer	0.000602	0.00112	CcSEcCtD
Loxapine—Oedema—Doxorubicin—testicular cancer	0.000597	0.00111	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000595	0.00111	CcSEcCtD
Loxapine—Fatigue—Methotrexate—testicular cancer	0.000594	0.00111	CcSEcCtD
Loxapine—Shock—Doxorubicin—testicular cancer	0.000587	0.00109	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—testicular cancer	0.000585	0.00109	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000584	0.00109	CcSEcCtD
Loxapine—Insomnia—Epirubicin—testicular cancer	0.000583	0.00109	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—testicular cancer	0.000582	0.00109	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—testicular cancer	0.000579	0.00108	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—testicular cancer	0.000575	0.00107	CcSEcCtD
Loxapine—Somnolence—Epirubicin—testicular cancer	0.000573	0.00107	CcSEcCtD
Loxapine—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	0.000569	0.00382	CbGpPWpGaD
Loxapine—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	0.000569	0.00381	CbGpPWpGaD
Loxapine—Feeling abnormal—Methotrexate—testicular cancer	0.000568	0.00106	CcSEcCtD
Loxapine—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	0.000564	0.00378	CbGpPWpGaD
Loxapine—Hypotension—Doxorubicin—testicular cancer	0.000558	0.00104	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000557	0.00104	CcSEcCtD
Loxapine—Fatigue—Epirubicin—testicular cancer	0.000556	0.00104	CcSEcCtD
Loxapine—Constipation—Epirubicin—testicular cancer	0.000552	0.00103	CcSEcCtD
Loxapine—HTR6—GPCR downstream signaling—INSL3—testicular cancer	0.000548	0.00367	CbGpPWpGaD
Loxapine—HTR7—GPCR downstream signaling—INSL3—testicular cancer	0.000547	0.00367	CbGpPWpGaD
Loxapine—HTR1D—GPCR downstream signaling—INSL3—testicular cancer	0.000543	0.00364	CbGpPWpGaD
Loxapine—Insomnia—Doxorubicin—testicular cancer	0.00054	0.00101	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—testicular cancer	0.000536	0.000999	CcSEcCtD
Loxapine—HTR1B—GPCR downstream signaling—INSL3—testicular cancer	0.000532	0.00357	CbGpPWpGaD
Loxapine—Dyspnoea—Doxorubicin—testicular cancer	0.000532	0.000992	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—testicular cancer	0.000531	0.000991	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—testicular cancer	0.000531	0.000989	CcSEcCtD
Loxapine—DRD4—GPCR downstream signaling—INSL3—testicular cancer	0.000524	0.00351	CbGpPWpGaD
Loxapine—CHRM4—GPCR downstream signaling—INSL3—testicular cancer	0.000517	0.00346	CbGpPWpGaD
Loxapine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000515	0.000961	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—testicular cancer	0.000515	0.000959	CcSEcCtD
Loxapine—Constipation—Doxorubicin—testicular cancer	0.00051	0.000952	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—testicular cancer	0.000508	0.000947	CcSEcCtD
Loxapine—HTR6—Signaling by GPCR—INSL3—testicular cancer	0.000497	0.00334	CbGpPWpGaD
Loxapine—HTR7—Signaling by GPCR—INSL3—testicular cancer	0.000497	0.00333	CbGpPWpGaD
Loxapine—CHRM5—GPCR downstream signaling—INSL3—testicular cancer	0.000495	0.00332	CbGpPWpGaD
Loxapine—Asthenia—Methotrexate—testicular cancer	0.000494	0.000922	CcSEcCtD
Loxapine—HRH4—Signaling Pathways—INSL3—testicular cancer	0.000494	0.00331	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—INSL3—testicular cancer	0.000493	0.00331	CbGpPWpGaD
Loxapine—Feeling abnormal—Doxorubicin—testicular cancer	0.000492	0.000917	CcSEcCtD
Loxapine—Pruritus—Methotrexate—testicular cancer	0.000488	0.000909	CcSEcCtD
Loxapine—HTR1B—Signaling by GPCR—INSL3—testicular cancer	0.000483	0.00324	CbGpPWpGaD
Loxapine—CHRM4—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000476	0.00319	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—INSL3—testicular cancer	0.000475	0.00319	CbGpPWpGaD
Loxapine—Hypersensitivity—Epirubicin—testicular cancer	0.000475	0.000886	CcSEcCtD
Loxapine—DRD1—GPCR downstream signaling—INSL3—testicular cancer	0.000471	0.00316	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—INSL3—testicular cancer	0.000469	0.00315	CbGpPWpGaD
Loxapine—DRD3—GPCR downstream signaling—INSL3—testicular cancer	0.000465	0.00312	CbGpPWpGaD
Loxapine—Asthenia—Epirubicin—testicular cancer	0.000463	0.000863	CcSEcCtD
Loxapine—Pruritus—Epirubicin—testicular cancer	0.000456	0.000851	CcSEcCtD
Loxapine—Dizziness—Methotrexate—testicular cancer	0.000456	0.00085	CcSEcCtD
Loxapine—CHRM5—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000456	0.00306	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—INSL3—testicular cancer	0.000449	0.00301	CbGpPWpGaD
Loxapine—Hypersensitivity—Doxorubicin—testicular cancer	0.00044	0.00082	CcSEcCtD
Loxapine—Vomiting—Methotrexate—testicular cancer	0.000438	0.000817	CcSEcCtD
Loxapine—Rash—Methotrexate—testicular cancer	0.000435	0.00081	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—testicular cancer	0.000434	0.00081	CcSEcCtD
Loxapine—Headache—Methotrexate—testicular cancer	0.000432	0.000805	CcSEcCtD
Loxapine—HTR1E—Signaling Pathways—INSL3—testicular cancer	0.00043	0.00288	CbGpPWpGaD
Loxapine—Asthenia—Doxorubicin—testicular cancer	0.000428	0.000798	CcSEcCtD
Loxapine—DRD1—Signaling by GPCR—INSL3—testicular cancer	0.000428	0.00287	CbGpPWpGaD
Loxapine—Dizziness—Epirubicin—testicular cancer	0.000427	0.000795	CcSEcCtD
Loxapine—ADRB1—GPCR downstream signaling—INSL3—testicular cancer	0.000424	0.00284	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—INSL3—testicular cancer	0.000422	0.00283	CbGpPWpGaD
Loxapine—Pruritus—Doxorubicin—testicular cancer	0.000422	0.000787	CcSEcCtD
Loxapine—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	0.00042	0.00282	CbGpPWpGaD
Loxapine—Vomiting—Epirubicin—testicular cancer	0.00041	0.000765	CcSEcCtD
Loxapine—Nausea—Methotrexate—testicular cancer	0.000409	0.000763	CcSEcCtD
Loxapine—Rash—Epirubicin—testicular cancer	0.000407	0.000758	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—testicular cancer	0.000406	0.000758	CcSEcCtD
Loxapine—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	0.000405	0.00272	CbGpPWpGaD
Loxapine—Headache—Epirubicin—testicular cancer	0.000404	0.000753	CcSEcCtD
Loxapine—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	0.000403	0.0027	CbGpPWpGaD
Loxapine—Dizziness—Doxorubicin—testicular cancer	0.000395	0.000736	CcSEcCtD
Loxapine—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	0.000392	0.00263	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	0.000386	0.00259	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—INSL3—testicular cancer	0.000385	0.00258	CbGpPWpGaD
Loxapine—Nausea—Epirubicin—testicular cancer	0.000383	0.000714	CcSEcCtD
Loxapine—HRH2—Signaling Pathways—INSL3—testicular cancer	0.000383	0.00257	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	0.000381	0.00256	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—INSL3—testicular cancer	0.000381	0.00255	CbGpPWpGaD
Loxapine—Vomiting—Doxorubicin—testicular cancer	0.000379	0.000708	CcSEcCtD
Loxapine—Rash—Doxorubicin—testicular cancer	0.000376	0.000702	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—testicular cancer	0.000376	0.000701	CcSEcCtD
Loxapine—Headache—Doxorubicin—testicular cancer	0.000374	0.000697	CcSEcCtD
Loxapine—HTR1A—Signaling by GPCR—INSL3—testicular cancer	0.000368	0.00247	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—INSL3—testicular cancer	0.000366	0.00246	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	0.000356	0.00239	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—INSL3—testicular cancer	0.000356	0.00239	CbGpPWpGaD
Loxapine—Nausea—Doxorubicin—testicular cancer	0.000354	0.000661	CcSEcCtD
Loxapine—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	0.000351	0.00235	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	0.00035	0.00235	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—INSL3—testicular cancer	0.000349	0.00234	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—INSL3—testicular cancer	0.000348	0.00234	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—INSL3—testicular cancer	0.000347	0.00233	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—INSL3—testicular cancer	0.000344	0.00231	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	0.000343	0.0023	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—INSL3—testicular cancer	0.000323	0.00217	CbGpPWpGaD
Loxapine—CHRM1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000321	0.00215	CbGpPWpGaD
Loxapine—CHRM3—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.00032	0.00214	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	0.000319	0.00214	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—INSL3—testicular cancer	0.000318	0.00213	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—INSL3—testicular cancer	0.000317	0.00213	CbGpPWpGaD
Loxapine—CHRM2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.000317	0.00212	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—INSL3—testicular cancer	0.000316	0.00212	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—INSL3—testicular cancer	0.000315	0.00211	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—INSL3—testicular cancer	0.000312	0.00209	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	0.000311	0.00209	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—INSL3—testicular cancer	0.000294	0.00197	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—INSL3—testicular cancer	0.000293	0.00197	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—INSL3—testicular cancer	0.000292	0.00196	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	0.000289	0.00194	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—INSL3—testicular cancer	0.000285	0.00191	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—INSL3—testicular cancer	0.000281	0.00188	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—INSL3—testicular cancer	0.000277	0.00186	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—INSL3—testicular cancer	0.000265	0.00178	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—H2AFZ—testicular cancer	0.000255	0.00171	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—STK11—testicular cancer	0.000253	0.0017	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—INSL3—testicular cancer	0.000253	0.0017	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—INSL3—testicular cancer	0.000249	0.00167	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—KITLG—testicular cancer	0.000235	0.00157	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—INSL3—testicular cancer	0.000227	0.00152	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—INSL3—testicular cancer	0.000225	0.00151	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—INSL3—testicular cancer	0.000217	0.00146	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—INSL3—testicular cancer	0.000216	0.00145	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—INSL3—testicular cancer	0.00021	0.00141	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—INSL3—testicular cancer	0.000207	0.00139	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—INSL3—testicular cancer	0.000191	0.00128	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—INSL3—testicular cancer	0.000188	0.00126	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—INSL3—testicular cancer	0.000187	0.00126	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—INSL3—testicular cancer	0.000187	0.00125	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—INSL3—testicular cancer	0.000186	0.00125	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—INSL3—testicular cancer	0.000184	0.00124	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—INSL3—testicular cancer	0.000184	0.00123	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—FGFR3—testicular cancer	0.000174	0.00117	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—INSL3—testicular cancer	0.000171	0.00115	CbGpPWpGaD
Loxapine—HTR5A—Signaling Pathways—KIT—testicular cancer	0.00016	0.00107	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—H2AFZ—testicular cancer	0.000158	0.00106	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—STK11—testicular cancer	0.000157	0.00105	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—KITLG—testicular cancer	0.000145	0.000976	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—H2AFZ—testicular cancer	0.000138	0.000923	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—STK11—testicular cancer	0.000137	0.000918	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—KITLG—testicular cancer	0.000127	0.000849	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—H2AFZ—testicular cancer	0.000123	0.000822	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—STK11—testicular cancer	0.000122	0.000818	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—H2AFZ—testicular cancer	0.000122	0.000817	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—STK11—testicular cancer	0.000121	0.000812	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—KITLG—testicular cancer	0.000113	0.000756	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—KITLG—testicular cancer	0.000112	0.000752	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—HPGDS—testicular cancer	0.00011	0.000739	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—FGFR3—testicular cancer	0.000108	0.000725	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—KIT—testicular cancer	9.93e-05	0.000666	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—HPGDS—testicular cancer	9.76e-05	0.000654	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—FGFR3—testicular cancer	9.41e-05	0.000631	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—H2AFZ—testicular cancer	9.4e-05	0.000631	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—H2AFZ—testicular cancer	9.39e-05	0.00063	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—STK11—testicular cancer	9.35e-05	0.000627	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—STK11—testicular cancer	9.34e-05	0.000626	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—H2AFZ—testicular cancer	9.33e-05	0.000626	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—STK11—testicular cancer	9.28e-05	0.000622	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—H2AFZ—testicular cancer	9.14e-05	0.000613	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—STK11—testicular cancer	9.08e-05	0.000609	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—H2AFZ—testicular cancer	8.99e-05	0.000603	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—HPGDS—testicular cancer	8.95e-05	0.0006	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—STK11—testicular cancer	8.94e-05	0.0006	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—H2AFZ—testicular cancer	8.87e-05	0.000595	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—STK11—testicular cancer	8.82e-05	0.000591	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—KITLG—testicular cancer	8.65e-05	0.00058	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—KIT—testicular cancer	8.64e-05	0.00058	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—KITLG—testicular cancer	8.64e-05	0.00058	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—KITLG—testicular cancer	8.58e-05	0.000576	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—H2AFZ—testicular cancer	8.49e-05	0.00057	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—STK11—testicular cancer	8.45e-05	0.000566	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—KITLG—testicular cancer	8.41e-05	0.000564	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—FGFR3—testicular cancer	8.38e-05	0.000562	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—FGFR3—testicular cancer	8.33e-05	0.000559	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—KITLG—testicular cancer	8.27e-05	0.000555	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—KITLG—testicular cancer	8.16e-05	0.000547	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—H2AFZ—testicular cancer	8.09e-05	0.000543	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—STK11—testicular cancer	8.05e-05	0.00054	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—STK11—testicular cancer	8.01e-05	0.000537	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—H2AFZ—testicular cancer	7.99e-05	0.000536	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—STK11—testicular cancer	7.94e-05	0.000533	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—KITLG—testicular cancer	7.81e-05	0.000524	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—KIT—testicular cancer	7.7e-05	0.000516	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—KIT—testicular cancer	7.65e-05	0.000513	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KITLG—testicular cancer	7.45e-05	0.000499	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KITLG—testicular cancer	7.35e-05	0.000493	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—H2AFZ—testicular cancer	7.28e-05	0.000488	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—STK11—testicular cancer	7.23e-05	0.000485	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	7.21e-05	0.000484	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—STK11—testicular cancer	7.17e-05	0.000481	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—STK11—testicular cancer	7.09e-05	0.000475	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	6.96e-05	0.000467	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	6.92e-05	0.000464	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STK11—testicular cancer	6.92e-05	0.000464	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STK11—testicular cancer	6.88e-05	0.000462	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	6.74e-05	0.000452	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STK11—testicular cancer	6.7e-05	0.000449	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KITLG—testicular cancer	6.69e-05	0.000449	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KITLG—testicular cancer	6.63e-05	0.000445	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	6.63e-05	0.000445	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STK11—testicular cancer	6.59e-05	0.000442	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—STK11—testicular cancer	6.5e-05	0.000436	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—FGFR3—testicular cancer	6.43e-05	0.000431	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—FGFR3—testicular cancer	6.42e-05	0.000431	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KITLG—testicular cancer	6.4e-05	0.000429	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—FGFR3—testicular cancer	6.38e-05	0.000428	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KITLG—testicular cancer	6.37e-05	0.000427	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—FGFR3—testicular cancer	6.25e-05	0.000419	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KITLG—testicular cancer	6.2e-05	0.000416	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—FGFR3—testicular cancer	6.15e-05	0.000412	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—H2AFZ—testicular cancer	6.11e-05	0.00041	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KITLG—testicular cancer	6.1e-05	0.000409	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STK11—testicular cancer	6.08e-05	0.000408	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—FGFR3—testicular cancer	6.06e-05	0.000407	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	6.01e-05	0.000403	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—H2AFZ—testicular cancer	6e-05	0.000402	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—H2AFZ—testicular cancer	5.98e-05	0.000401	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STK11—testicular cancer	5.98e-05	0.000401	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STK11—testicular cancer	5.97e-05	0.0004	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—H2AFZ—testicular cancer	5.96e-05	0.0004	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STK11—testicular cancer	5.95e-05	0.000399	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STK11—testicular cancer	5.93e-05	0.000398	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—H2AFZ—testicular cancer	5.9e-05	0.000396	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—KIT—testicular cancer	5.9e-05	0.000396	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—KIT—testicular cancer	5.9e-05	0.000395	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	5.89e-05	0.000395	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STK11—testicular cancer	5.87e-05	0.000394	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—KIT—testicular cancer	5.86e-05	0.000393	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STK11—testicular cancer	5.85e-05	0.000393	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—FGFR3—testicular cancer	5.81e-05	0.00039	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—KIT—testicular cancer	5.74e-05	0.000385	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—KIT—testicular cancer	5.64e-05	0.000379	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KITLG—testicular cancer	5.62e-05	0.000377	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—KIT—testicular cancer	5.57e-05	0.000373	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—FGFR3—testicular cancer	5.53e-05	0.000371	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KITLG—testicular cancer	5.53e-05	0.000371	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KITLG—testicular cancer	5.52e-05	0.00037	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KITLG—testicular cancer	5.5e-05	0.000369	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KITLG—testicular cancer	5.48e-05	0.000368	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	5.47e-05	0.000367	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—FGFR3—testicular cancer	5.46e-05	0.000366	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STK11—testicular cancer	5.44e-05	0.000365	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KITLG—testicular cancer	5.43e-05	0.000364	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KITLG—testicular cancer	5.42e-05	0.000363	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—KIT—testicular cancer	5.33e-05	0.000358	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KIT—testicular cancer	5.08e-05	0.000341	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KITLG—testicular cancer	5.03e-05	0.000338	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KIT—testicular cancer	5.01e-05	0.000336	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—FGFR3—testicular cancer	4.98e-05	0.000334	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	4.93e-05	0.000331	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—FGFR3—testicular cancer	4.76e-05	0.000319	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—FGFR3—testicular cancer	4.73e-05	0.000318	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	4.6e-05	0.000309	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KIT—testicular cancer	4.57e-05	0.000306	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	4.53e-05	0.000304	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KIT—testicular cancer	4.53e-05	0.000304	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KIT—testicular cancer	4.37e-05	0.000293	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KIT—testicular cancer	4.35e-05	0.000292	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KIT—testicular cancer	4.23e-05	0.000284	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—FGFR3—testicular cancer	4.18e-05	0.00028	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KIT—testicular cancer	4.16e-05	0.000279	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—FGFR3—testicular cancer	4.11e-05	0.000276	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—FGFR3—testicular cancer	4.1e-05	0.000275	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—FGFR3—testicular cancer	4.09e-05	0.000274	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—FGFR3—testicular cancer	4.08e-05	0.000273	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—FGFR3—testicular cancer	4.04e-05	0.000271	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	4.03e-05	0.00027	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KIT—testicular cancer	3.84e-05	0.000257	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KIT—testicular cancer	3.77e-05	0.000253	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KIT—testicular cancer	3.77e-05	0.000253	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KIT—testicular cancer	3.75e-05	0.000252	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KIT—testicular cancer	3.74e-05	0.000251	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	3.74e-05	0.000251	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KIT—testicular cancer	3.71e-05	0.000249	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KIT—testicular cancer	3.7e-05	0.000248	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KIT—testicular cancer	3.43e-05	0.00023	CbGpPWpGaD
